Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 88Leukemia 7Lymphoma, Follicular 6Leukemia, B-Cell 6Neoplasms 5Lymphoma, B-Cell, Marginal Zone 4Lymphoma, B-Cell 4Leukemia, Hairy Cell 4Lymphoma 3Lymphoma, Mantle-Cell 2Bronchiolitis Obliterans Syndrome 2Waldenstrom Macroglobulinemia 1Tumor Lysis Syndrome 1Recurrence 1Neoplasm, Residual 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphatic Diseases 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphoid 1Hereditary Sensory and Autonomic Neuropathies 1Heart Failure 1Disease 1Chromosome 17 deletion 1Anemia 1

Interventions

ibrutinib 8fludarabine 8fludarabine phosphate 7Cyclophosphamide 7Busulfan 6blinatumomab 5Rituximab 5Whole-Body Irradiation 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Melphalan 4Methotrexate 3Mesna 3Lenalidomide 3Bone Marrow Transplantation 3Bendamustine Hydrochloride 3thymoglobulin 2pirtobrutinib 2Vincristine 2Patient Reported Outcome Measures 2Doxorubicin 2Biopsy 2Behavior Therapy 2Alemtuzumab 2venetoclax 1tozasertib 1sargramostim 1romiplostim 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphoid × obinutuzumab × Other hematologic neoplasm × Clear all
NCT01680991 2016-04-25

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Hoffmann-La Roche

Phase 1 Completed
48 enrolled 27 charts
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡